Similarly, Renshen Guben oral liquid (RSGB), a formula approved by the National Medical Products Administration (NMPA) of China, has been shown to mitigate renal fibrosis via the TGFβ1/Smad2/3, Wnt4/β-catenin, and NGFR/NF-κB pathways (Zhang et al., 2023). The gene discussed is TGFB1; the disease is renal fibrosis.